Myriad Genetics, Inc. (MYGN): Price and Financial Metrics

Myriad Genetics, Inc. (MYGN)

Today's Latest Price: $11.47 USD

0.03 (0.26%)

Updated Jul 10 4:00pm

Add MYGN to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 58 in Medical - Diagnostics/Research

See all "A" rated Strong Buy stocks

MYGN Stock Summary

  • MYGN's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.85 -- higher than merely 19.55% of US-listed equities with positive expected earnings growth.
  • In terms of twelve month growth in earnings before interest and taxes, Myriad Genetics Inc is reporting a growth rate of -680.94%; that's higher than merely 2.89% of US stocks.
  • The volatility of Myriad Genetics Inc's share price is greater than that of 80.85% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to Myriad Genetics Inc, a group of peers worth examining would be HBIO, KVHI, DSS, CCUR, and DHX.
  • MYGN's SEC filings can be seen here. And to visit Myriad Genetics Inc's official web site, go to
MYGN Daily Price Range
MYGN 52-Week Price Range

MYGN Stock Price Chart Technical Analysis Charts

MYGN Price/Volume Stats

Current price $11.47 52-week high $48.40
Prev. close $11.44 52-week low $9.24
Day low $11.05 Volume 785,602
Day high $11.73 Avg. volume 1,172,057
50-day MA $13.68 Dividend yield N/A
200-day MA $20.81 Market Cap 855.15M

Myriad Genetics, Inc. (MYGN) Company Bio

Myriad Genetics discovers and commercializes molecular diagnostic tests that; determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties to improve patient care. The company was founded in 1991 and is based in Salt Lake City, Utah.

MYGN Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:

We started the process of determining a valid price forecast for Myriad Genetics Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Myriad Genetics Inc ranked in the 18th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. In terms of the factors that were most noteworthy in this DCF analysis for MYGN, they are:

  • The company's compound free cash flow growth rate over the past 5.5 years comes in at -0.08%; that's greater than merely 18.67% of US stocks we're applying DCF forecasting to.
  • Myriad Genetics Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -14.82. This coverage rate is greater than that of just 6.49% of stocks we're observing for the purpose of forecasting via discounted cash flows.
  • The weighted average cost of capital for the company is 11. This value is greater than 87.45% stocks in the Healthcare sector that generate free cash flow.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as MYGN, try ARA, EW, PRGO, VAR, and VIVO.

MYGN Latest News Stream

Event/TimeNews Detail
Loading, please wait...

MYGN Latest Social Stream

Loading social stream, please wait...

View Full MYGN Social Stream

Latest MYGN News From Around the Web

Below are the latest news stories about Myriad Genetics Inc that investors may wish to consider to help them evaluate MYGN as an investment opportunity.

Myriad Genetics, OptraHEALTH Partner to Offer Cancer Knowledge

Myriad Genetics (MYGN) collaborates with OptraHEALTH to provide an AI-powered cognitive ChatBOT to serve as a genetic health knowledge platform to prospective hereditary cancer patients.

Yahoo | July 7, 2020

Myriad Announces New Studies Validating the Ability of Myriad’s riskScore® Test to Modify Breast Cancer Risk Prediction

Myriad Genetics, Inc. (MYGN), a leader in molecular diagnostics and precision medicine, announced today two recent publications validating the polygenic risk score (PRS) component of Myriad’s breast cancer risk stratification tool riskScore®. The publications clinically validate both the ability of the PRS component of riskScore to predict breast cancer risk in asymptomatic women and modify risk estimations for patients identified with pathogenic mutations.

Yahoo | July 7, 2020

Myriad Genetics Rides on EndoPredict Amid Coronavirus Crisis

Myriad Genetics (MYGN) expects to register an uptick in hereditary cancer volumes on account of its contract with UnitedHealthcare.

Yahoo | July 6, 2020

Myriad Announces Partnership with OptraHEALTH® to Deliver “Gene™” a New AI Based Information Tool for Hereditary Cancer Patients

Myriad Genetics, Inc. (MYGN), a leader in molecular diagnostics and precision medicine, today announced a new collaboration with OptraHEALTH® to implement a cognitive ChatBOT named Gene™  to provide genetic and financial assistance information to prospective patients. Gene is an AI-powered, HIPAA-compliant knowledge platform for genetic health with BOT interfaces and can answer over 500,000 health related questions pertaining to hereditary cancer. Gene interfaces with Myriad’s market leading online hereditary cancer quiz, which is now taken by approximately one million people per year.

Yahoo | July 6, 2020

Hedge Funds Never Been Less Bullish On Myriad Genetics, Inc. (MYGN)

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]

Yahoo | July 6, 2020

Read More 'MYGN' Stories Here

MYGN Price Returns

1-mo -4.50%
3-mo -24.24%
6-mo -60.85%
1-year -55.40%
3-year -54.74%
5-year -66.03%
YTD -57.88%
2019 -6.33%
2018 -15.36%
2017 106.03%
2016 -61.38%
2015 26.72%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8803 seconds.